Skip to content

A Clinical Trial To Evaluate The Action OF Duralabhadi Decoction In The Management Of Urinary Tract Infections.

A Clinical Trial To Evaluate The Effectiveness Of Duralabhadi Kashaya In The Management Of Urinary Tract Infections. - NIL

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/07/055121
Enrollment
24
Registered
2023-07-12
Start date
Unknown
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N00-N99- Diseases of the genitourinary system Health Condition 2: N30-N39- Other diseases of the urinary system

Interventions

None listed

Sponsors

NIL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Subjects of either gender between age group 20-60 yrs 2)Subjects diagnosed with pus cell / bacteria in urine routine examination 3)Subjects diagnosed on basis of diagnostic parameters 4)Subjects willing to sign the consent form and agreeing to follow the protocol of the study

Exclusion criteria

Exclusion criteria: 1)Subjects with known case of impaired renal function 2)Subjects with known case of malignancy or tuberculosis of urinary tract 3)Subjects with known case of Diabetes Mellitus 4)Subjects with known case of Urolithiasis 5)Women those who are pregnant and breast feeding

Design outcomes

Primary

MeasureTime frame
Subjective parameters like Dysuria Increased frequency of micturition Urgency of micturition Supra pubic discomfort Fever Timepoint: Objective parameters like Urine routine examination assessed on 0th day, 6th day, 11th day, 16th day & 31st urine culture is done on 0th day, 16th day and 31st

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDr ARUN PRATAP

Pankajakasthuri Ayurveda Medical College & PG Centre

mahadevan101@gmail.com9567256333

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026